These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
638 related articles for article (PubMed ID: 15180922)
1. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Sufan RI; Jewett MA; Ohh M Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922 [TBL] [Abstract][Full Text] [Related]
2. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493 [TBL] [Abstract][Full Text] [Related]
3. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Kaelin WG Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019 [TBL] [Abstract][Full Text] [Related]
4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
5. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Maynard MA; Ohh M Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728 [TBL] [Abstract][Full Text] [Related]
6. Role of VHL gene mutation in human cancer. Kim WY; Kaelin WG J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513 [TBL] [Abstract][Full Text] [Related]
7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
8. Identification of novel VHL target genes and relationship to hypoxic response pathways. Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735 [TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918 [TBL] [Abstract][Full Text] [Related]
10. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Petrella BL; Lohi J; Brinckerhoff CE Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504 [TBL] [Abstract][Full Text] [Related]
11. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750 [TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612 [TBL] [Abstract][Full Text] [Related]
13. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613 [TBL] [Abstract][Full Text] [Related]
14. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Kaelin WG Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749 [TBL] [Abstract][Full Text] [Related]
15. Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma. Choi JW; Park SC; Kang GH; Liu JO; Youn HD Cancer Res; 2004 Jan; 64(1):35-9. PubMed ID: 14729605 [TBL] [Abstract][Full Text] [Related]
16. The von Hippel-Lindau tumor suppressor gene. Kondo K; Kaelin WG Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528 [TBL] [Abstract][Full Text] [Related]
17. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Zbar B Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521 [TBL] [Abstract][Full Text] [Related]
18. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344 [TBL] [Abstract][Full Text] [Related]
19. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071 [TBL] [Abstract][Full Text] [Related]
20. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]